This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Eisai R&d Management Co., Ltd.. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: Taisuke Hoshi: Innovator in Hepatocellular Carcinoma Therapy
Introduction
Taisuke Hoshi is a notable inventor based in Tsukubamirai, Japan. He has made significant contributions to the field of medical research, particularly in the area of hepatocellular carcinoma therapy. His work focuses on developing biomarkers that can predict patient responses to specific treatments.
Latest Patents
Hoshi holds a patent for "Biomarkers for a therapy comprising a sorafenib compound." This patent provides biomarkers that predict whether a subject with hepatocellular carcinoma is responsive to therapy involving sorafenib or its pharmaceutically acceptable salts. The biomarkers, compositions, and methods described in this patent are instrumental in selecting appropriate treatment modalities for patients at risk of developing or already diagnosed with hepatocellular carcinoma.
Career Highlights
Taisuke Hoshi is associated with Eisai R&D Management Co., Ltd., where he continues to advance his research in cancer therapies. His innovative approach has garnered attention in the medical community, contributing to the development of more effective treatment options for patients.
Collaborations
Hoshi has collaborated with esteemed colleagues, including Yukinori Minoshima and Michio Kanekiyo. These partnerships have enhanced the research efforts and broadened the impact of their findings in the field of oncology.
Conclusion
Taisuke Hoshi's work in developing biomarkers for hepatocellular carcinoma therapy exemplifies the importance of innovation in medical research. His contributions are paving the way for more personalized and effective treatment strategies for patients facing this challenging disease.